blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3129785

EP3129785 - DIAGNOSIS OF CANCER BY DETECTING DIMERIC IL-18 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.01.2020
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  25.01.2019
FormerGrant of patent is intended
Status updated on  16.09.2018
FormerExamination is in progress
Status updated on  14.07.2017
FormerRequest for examination was made
Status updated on  13.01.2017
FormerThe international publication has been made
Status updated on  09.11.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Randox Laboratories Ltd.
Ardmore, Diamond Road
Crumlin
Co. Antrim, Northern Ireland BT29 4QY / GB
[2017/07]
Inventor(s)01 / CHACKO, Alex
Randox Laboratories Ltd
Ardmore Diamond Road
Co Antrim Northern Ireland BT29 4QY / GB
02 / MCCONNELL, Ivan
Randox Laboratories Ltd
Ardmore Diamond Road
Crumlin Co Antrim Northern Ireland BT29 4QY / GB
03 / FITZGERALD, Peter
Randox Laboratories Ltd
Ardmore Diamond Road
Co Antrim Northern Ireland BT29 4QY / GB
04 / LAMONT, John V.
Randox Laboratories Ltd.
Ardmore
55 Diamond Road
Crumlin
Co. Antrim Northern Ireland BT29 4QY / GB
 [2017/07]
Representative(s)Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
[2017/07]
Application number, filing date15715807.202.04.2015
[2017/07]
WO2015GB51052
Priority number, dateGB2014000639809.04.2014         Original published format: GB 201406398
GB2015000141528.01.2015         Original published format: GB 201501415
[2017/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015155513
Date:15.10.2015
Language:EN
[2015/41]
Type: A1 Application with search report 
No.:EP3129785
Date:15.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 15.10.2015 takes the place of the publication of the European patent application.
[2017/07]
Type: B1 Patent specification 
No.:EP3129785
Date:27.02.2019
Language:EN
[2019/09]
Search report(s)International search report - published on:EP15.10.2015
ClassificationIPC:G01N33/574
[2017/07]
CPC:
G01N33/57484 (EP,US); A61P35/00 (EP,US); A61P35/04 (EP,US);
G01N33/53 (US); G01N33/57423 (US); G01N33/6869 (EP,US);
C07K14/54 (US); G01N2333/54 (US); G01N2800/52 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/07]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:KREBSDIAGNOSE DURCH DEN NACHWEIS VON DIMEREM IL-18[2018/34]
English:DIAGNOSIS OF CANCER BY DETECTING DIMERIC IL-18[2017/07]
French:DIAGNOSE DU CANCER PAR LA DÉTECTION DE IL-18 DIMERIQUE[2018/34]
Former [2017/07]DIAGNOSE VON KREBS DURCH NACHWEIS VON DIMEREM IL-18
Former [2017/07]DIAGNOSTIC DU CANCER PAR DÉTECTION D'IL-18 DIMÉRIQUE
Entry into regional phase10.10.2016National basic fee paid 
10.10.2016Designation fee(s) paid 
10.10.2016Examination fee paid 
Examination procedure10.10.2016Examination requested  [2017/07]
10.10.2016Date on which the examining division has become responsible
19.05.2017Amendment by applicant (claims and/or description)
13.07.2017Despatch of a communication from the examining division (Time limit: M06)
22.01.2018Reply to a communication from the examining division
19.02.2018Despatch of a communication from the examining division (Time limit: M06)
28.06.2018Reply to a communication from the examining division
17.09.2018Communication of intention to grant the patent
14.01.2019Fee for grant paid
14.01.2019Fee for publishing/printing paid
14.01.2019Receipt of the translation of the claim(s)
Opposition(s)28.11.2019No opposition filed within time limit [2020/06]
Fees paidRenewal fee
28.04.2017Renewal fee patent year 03
30.04.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.04.2015
AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
MK27.02.2019
MT27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
LU02.04.2019
FR27.04.2019
BE30.04.2019
CH30.04.2019
LI30.04.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
[2022/31]
Former [2021/34]HU02.04.2015
AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
MT27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
LU02.04.2019
FR27.04.2019
BE30.04.2019
CH30.04.2019
LI30.04.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2021/32]HU02.04.2015
AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
LU02.04.2019
FR27.04.2019
BE30.04.2019
CH30.04.2019
LI30.04.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2021/26]AL27.02.2019
AT27.02.2019
CY27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
LU02.04.2019
FR27.04.2019
BE30.04.2019
CH30.04.2019
LI30.04.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2020/17]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
TR27.02.2019
LU02.04.2019
FR27.04.2019
BE30.04.2019
CH30.04.2019
LI30.04.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2020/11]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SI27.02.2019
SK27.02.2019
SM27.02.2019
LU02.04.2019
FR27.04.2019
BE30.04.2019
CH30.04.2019
LI30.04.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2020/04]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
SM27.02.2019
LU02.04.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2020/03]AL27.02.2019
AT27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
SM27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2020/01]AL27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
MC27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
SM27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/52]AL27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
PL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
SM27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/51]AL27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
SM27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/49]AL27.02.2019
CZ27.02.2019
DK27.02.2019
EE27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RO27.02.2019
RS27.02.2019
SE27.02.2019
SK27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/48]DK27.02.2019
ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/47]ES27.02.2019
FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/46]FI27.02.2019
HR27.02.2019
IT27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/39]FI27.02.2019
HR27.02.2019
LT27.02.2019
LV27.02.2019
NL27.02.2019
RS27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
IS27.06.2019
PT27.06.2019
Former [2019/38]FI27.02.2019
LT27.02.2019
SE27.02.2019
BG27.05.2019
NO27.05.2019
GR28.05.2019
PT27.06.2019
Former [2019/37]FI27.02.2019
LT27.02.2019
SE27.02.2019
NO27.05.2019
GR28.05.2019
PT27.06.2019
Former [2019/34]FI27.02.2019
LT27.02.2019
SE27.02.2019
NO27.05.2019
PT27.06.2019
Former [2019/33]FI27.02.2019
LT27.02.2019
NO27.05.2019
PT27.06.2019
Cited inInternational search[XI]  - SEYA T ET AL, "Protein polymorphism of human IL-18 identified by monoclonal antibodies", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS PUBLICATIONS, GR, vol. 8, no. 5, doi:10.3892/IJMM.8.5.585, ISSN 1107-3756, (20011101), pages 585 - 590, (20111001), XP008176540 [X] 1-3,29-37 * abstract * * page 587 - page 588 * [I] 4-12,39,40

DOI:   http://dx.doi.org/10.3892/ijmm.8.5.585
 [XI]  - T SEYA ET AL, "114: Novel proforms of IL-18 are produced in human Langerhans cells, macrophages and mature dendritic cells but not monocytes", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, GB, (20000101), vol. 114, no. 1, doi:10.1046/j.1523-1747.2000.01141.x, ISSN 0022-202X, page 228, XP055193462 [X] 1-3,29-37 * abstract * [I] 4-12,39,40

DOI:   http://dx.doi.org/10.1046/j.1523-1747.2000.01141.x
 [X]  - KIKKAWA S ET AL, "A COMPARATIVE ANALYSIS OF THE ANTIGENIC, STRUCTURAL, AND FUNCTIONAL PROPERTIES OF THREE DIFFERENT PREPARATIONS OF RECOMBINANT HUMAN INTERLEUKIN-18", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, (20000201), vol. 20, no. 2, doi:10.1089/107999000312586, ISSN 1079-9907, pages 179 - 185, XP001008267 [X] 32-36 * abstract * * page 180 - page 181; figure 1 *

DOI:   http://dx.doi.org/10.1089/107999000312586
 [X]  - SATOMI KIKKAWA ET AL, "Human Macrophages Produce Dimeric Forms of IL-18 Which Can Be Detected with Monoclonal Antibodies Specific for Inactive IL-18", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (20010201), vol. 281, no. 2, doi:10.1006/bbrc.2001.4378, ISSN 0006-291X, pages 461 - 467, XP055193673 [X] 32-36 * abstract *

DOI:   http://dx.doi.org/10.1006/bbrc.2001.4378
 [X]  - K SHIDA ET AL, "High serum levels of additional IL-18 forms may be reciprocally correlated with IgE levels in patients with atopic dermatitis", IMMUNOLOGY LETTERS, (20011203), vol. 79, no. 3, doi:10.1016/S0165-2478(01)00290-5, ISSN 0165-2478, pages 169 - 175, XP055193675 [X] 32-36 * abstract * * page 170 - page 171 *

DOI:   http://dx.doi.org/10.1016/S0165-2478(01)00290-5
 [X]  - K. SHIDA ET AL, "An Alternative Form of IL-18 in Human Blood Plasma: Complex Formation with IgM Defined by Monoclonal Antibodies", THE JOURNAL OF IMMUNOLOGY, (20010601), vol. 166, no. 11, doi:10.4049/jimmunol.166.11.6671, ISSN 0022-1767, pages 6671 - 6679, XP055193677 [X] 32-36 * figure 1 *

DOI:   http://dx.doi.org/10.4049/jimmunol.166.11.6671
 [I]  - Masaki Okamoto ET AL, "Correlation of Decreased Survival and IL-18 in Bone Metastasis", Internal Medicine, Japan, doi:10.2169/internalmedicine.48.1851, (20090515), pages 763 - 773, URL: http://jlc.jst.go.jp/JST.JSTAGE/internalmedicine/48.1851?from=SUMMON, (20150604), XP055193683 [I] 1-40 * abstract *

DOI:   http://dx.doi.org/10.2169/internalmedicine.48.1851
 [I]  - CARBONE ANNA ET AL, "IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival", JOURNAL OF IMMUNOTHERAPY, (200911), vol. 32, no. 9, ISSN 1524-9557, pages 920 - 931, XP008176543 [I] 1-40 * abstract *

DOI:   http://dx.doi.org/10.1097/CJI.0b013e3181b29168
 [I]  - Shailendra Dwivedi et al, "Diagnostic and Prognostic Significance of Prostate Specific Antigen and Serum Interleukin 18 and 10 in Patients with Locally Advanced Prostate Cancer: A Prospective Study", Asian Pacific Journal of Cancer Prevention J Cancer Prev, vol. 12, no. 7, (20110101), pages 1843 - 1848, URL: http://www.apocpcontrol.org/paper_file/issue_abs/Volume12_No7/1843-1848 c 6.27 Shailendra Dwivedi.pdf, (20150604), XP055193692 [I] 1-40 * abstract *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.